http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein. However, a research team, led by investigators at Weill Cornell Medical College, now report that these agents may, in fact, help a much broader cross section of lymphoma patients. http://medicalxpress.com/news/2013-05-master-majority-lymphoma.html Cancer Mon, 13 May 2013 16:51:34 EST news287682685 (HealthDay)—A new treatment approach may mean that young people with a form of lymphoma can go without radiation therapy, sparing them side effects or raised cancer risks down the road. http://medicalxpress.com/news/2013-04-strategy-young-lymphoma-patients-treatment.html Cancer Wed, 10 Apr 2013 18:50:01 EST news284834743 Ohio State University cancer researchers have identified molecules in the bloodstream that might accurately gauge the likelihood of radiation illness after exposure to ionizing radiation. http://medicalxpress.com/news/2013-02-small-molecules-blood-gauge-effects.html Cancer Mon, 25 Feb 2013 17:00:03 EST news281010315 The majority of people afflicted with cancer now recover with treatment. Many of these, however, subsequently experience new health problems due to the cancer and/or the treatment. Norwegian researchers want to find out why. http://medicalxpress.com/news/2013-02-cancer-poor-health.html Cancer Fri, 15 Feb 2013 10:10:02 EST news280143085 Think of the epigenome like a giant musical mixing board, turning up or down the expression of various genes. A University of Colorado Cancer Center study published today in the journal PLOS Genetics shows that in cancer, not only can genes themselves go bad, but abnormal changes in the epigenetic mixing board can unfortunately change the expression of these genes. Researchers hope to play the role of sound engineers, controlling these harmful epigenomic changes to turn down cancer itself or perhaps sensitize cancers to existing drugs. http://medicalxpress.com/news/2013-01-epigenomic-abnormalities-patient-survival-non-hodgkins.html Genetics Thu, 10 Jan 2013 17:00:01 EST news277046216 Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell – DLBCL (ABC-DLBCL), remains a major therapeutic challenge. An international research team, led by two laboratories from Weill Cornell Medical College, has developed a new experimental drug therapy to target this aggressive form of lymphoma. http://medicalxpress.com/news/2012-12-drug-therapy-aggressive-non-hodgkin-lymphoma.html Cancer Mon, 10 Dec 2012 15:46:52 EST news274376793 In the first broad genetic landscape mapped of a Burkitt lymphoma tumor, scientists at Duke Medicine and their collaborators identified 70 mutations, including several that had not previously been associated with cancer and a new one that was unique to the disease. http://medicalxpress.com/news/2012-11-genome-sequencing-burkitt-lymphoma-reveals.html Genetics Mon, 12 Nov 2012 11:03:27 EST news271940597 (HealthDay)—Treatment of lymphoma patients with the gonadotropin-releasing hormone agonist (GnRHa) triptorelin plus norethisterone does not reduce the rate of chemotherapy-induced premature ovarian failure (POF), according to a study published online Nov. 5 in the Journal of Clinical Oncology. http://medicalxpress.com/news/2012-11-triptorelin-doesnt-avert-early-ovarian.html Cancer Wed, 07 Nov 2012 15:30:02 EST news271523153 UK scientists hope that lymphoma patients could benefit from a new drug that triggers the cancer-fighting properties of the body's own immune system, after highly promising early laboratory results. http://medicalxpress.com/news/2012-10-scientists-harness-immune-lymphoma-relapse.html Cancer Thu, 18 Oct 2012 12:00:14 EST news269779296 (Medical Xpress)—Women respond much better than men to the treatment of chronic follicular lymphoma with a monoclonal antibody that targets CD20 (rituximab). These are the findings of a multi-centre, Austria-wide study by the Arbeitsgemeinschaft medikamentöse Tumortherapie (AGMT) carried out under the supervision of the University Department of Internal Medicine I and study leader Ulrich Jäger, which has now been published in the journal Haematologica. It was also discovered that the volume of lymphoma cells has an important role to play. http://medicalxpress.com/news/2012-10-women-treatment-lymph-gland-cancer.html Cancer Wed, 10 Oct 2012 08:27:35 EST news269076437 Melanoma is on the rise nationally, and transplant recipients and lymphoma patients are far likelier than the average person to get that form of skin cancer and to die from it, a Mayo Clinic review has found. That is because their immune systems tend to be significantly depressed, making early detection of melanoma even more important, says co-author Jerry Brewer, M.D., a Mayo dermatologist. The findings are published in the October issue of Mayo Clinic Proceedings. http://medicalxpress.com/news/2012-10-melanoma-likelier-transplant-lymphoma-patients.html Cancer Wed, 03 Oct 2012 13:18:36 EST news268489082 (HealthDay)—MYD88 L265P is a common, recurring mutation in patients with Waldenström's macroglobulinemia, according to a study published in the Aug. 30 issue of the New England Journal of Medicine. http://medicalxpress.com/news/2012-08-mutation-idd-waldenstrom-macroglobulinemia.html Cancer Thu, 30 Aug 2012 10:13:22 EST news265540374 Leukemia and lymphoma patients who receive life-saving stem cell or bone marrow transplants often experience chronic side effects that significantly decrease quality of life, can last a lifetime, and ultimately affect their long-term survival. http://medicalxpress.com/news/2012-08-cell-survival-key-chronic-graft.html Diseases, Conditions, Syndromes Thu, 16 Aug 2012 10:04:25 EST news264330235 A new cancer drug with remarkably few side effects is dramatically improving survival in Hodgkin lymphoma patients who fail other treatments and are nearly out of options. http://medicalxpress.com/news/2012-06-drug-survival-hodgkin-lymphoma-patients.html Cancer Wed, 27 Jun 2012 10:44:47 EST news260012675 A multicenter trial showed that nearly half of young patients with early-stage Hodgkin lymphoma can be cured without undergoing either irradiation or intensive chemotherapy that would leave them at risk for second cancers, infertility, heart and other problems later. http://medicalxpress.com/news/2012-06-quest-treatment-pediatric-hodgkin-lymphoma.html Cancer Tue, 26 Jun 2012 16:00:07 EST news259940424 A substantial proportion of NK/T-cell lymphomas harbor Janus Kinase 3 gene mutations. Patients with these lymphomas might benefit from treatment with a Janus Kinase inhibitor according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research. http://medicalxpress.com/news/2012-06-mutations-jak3-gene-subtype-lymphoma.html Cancer Fri, 15 Jun 2012 11:06:51 EST news258977203 A new compound that targets anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer is well-tolerated by patients and is already showing early signs of activity, including in patients who no longer respond to crizotinib—the only approved ALK inhibitor. Results of this Novartis-sponsored sudy will be presented by a researcher from Fox Chase Cancer Center during the 2012 Annual Meeting of the American Society of Clinical Oncology on Sunday, June 3. http://medicalxpress.com/news/2012-06-therapy-horizon-alk-non-small-cell.html Cancer Fri, 01 Jun 2012 19:26:14 EST news257797471 (HealthDay) -- For children with Hodgkin's lymphoma who respond to chemotherapy, treatment with low-dose involved-field radiation therapy (IFRT) improves event-free survival (EFS), but has no significant impact on overall survival (OS), in long-term follow-up, according to a study published online May 29 in the Journal of Clinical Oncology. http://medicalxpress.com/news/2012-05-ups-event-free-survival-ped-hodgkin.html Cancer Thu, 31 May 2012 18:50:01 EST news257707104 High-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT), for previously untreated patients with advanced follicular lymphoma (FL) does not improve overall survival compared with conventional-dose chemotherapy alone, according to an online study published December 21 in the Journal of the National Cancer Institute. http://medicalxpress.com/news/2011-12-autologous-stem-cell-transplantation-os.html Cancer Wed, 21 Dec 2011 16:00:01 EST news243694806 Younger patients with diffuse large B-cell lymphoma given a more intensive regimen of chemotherapy combined with rituximab survive significantly longer, and are approximately twice as likely to remain in remission 3 years later, compared with patients given standard chemotherapy treatment plus rituximab, according to an article published Online First in the Lancet. http://medicalxpress.com/news/2011-11-intensive-chemotherapy-recurrence-survival-younger.html Cancer Thu, 24 Nov 2011 18:30:03 EST news241362774 A three-pronged immunotherapy approach nearly doubles five-year survival among patients with rare leukemic form of cutaneous T-cell lymphoma, reports a new study by dermatologists from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania. http://medicalxpress.com/news/2011-08-triple-therapy-regime-patients-leukemic.html Cancer Mon, 15 Aug 2011 16:00:58 EST news232641679 Researchers at the University of Southampton have discovered clues to why many patients do not respond to a standard drug for the blood cancer lymphoma, raising hopes that more effective treatments can be designed. http://medicalxpress.com/news/2011-08-blood-cancer-breakthrough.html Cancer Wed, 10 Aug 2011 11:27:30 EST news232194074 Scientists at the BC Cancer Agency in British Columbia, Canada and their U.S. collaborators have identified a number of new genetic mutations involved in non-Hodgkin lymphoma, or NHL. http://medicalxpress.com/news/2011-07-genetic-mutations-non-hodgkin-lymphoma.html Cancer Thu, 28 Jul 2011 04:17:46 EST news231045427